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Potential Add-On and Growth Plan
Risk Profile
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Value Creation Strategy – Overview
The value creation strategy aims at the acceleration of the firm’s existing business units and the 
reinforcement of its international presence
Internationalization ReinforcementOrganic Growth Acceleration
The proposed investment in BioTel is expected to create significant value, driven by two key strategies: the acceleration of organic growth in the existing business units and the reinforcement of the
firm’s international presence, with a focus on the EMEA market.
Leverage cardiac expertise and partner with CROs: Reinforcement of partnerships with
laboratories, physicians and large CROs will win further sub-contracted clinical trials for
which cardiac expertise is required.
BioTel, currently mainly operating in the US, will reinforce its international presence in the
Nordics, Germany, and Israel through recent and future acquisitions of relevant players:
Strengthen BioTel’s EU presence: By leveraging the products, distribution network and
location of the recent acquisition, Sweden-based ADEA Medical, BioTel will accelerate its
presence in the attractive Nordic and EU markets.
Consolidation of EMEA market: Through the acquisition of SHL Telemedicine, the 2nd
largest direct competitor, BioTel will kickstart its presence in the German and Israeli markets,
also leveraging SHL’s distribution network and intellectual property.
Enlargement of the sales force and efficiency improvement: Further investments in the
size of the sales force and focus on sales efficiency will drive the number of sales accounts
(practices).
Reinforce market leadership in strongly growing market: Strong focus on the
development and sale of the flagship devices and services will maintain the leading position
in an attractive market that will see an increase in the total number of patients.
Leverage the Geneva Platform and expand customer base: Cross-selling the Geneva
Software Platform to existing BioTel Heart sales accounts (practices) will boost the revenue
coming from this technologically advanced software solution.
Diversification of BioTel Care’s customer base: With an increasing marketing and sales
effort towards institutions, such as Employer or Elderly/Home Care Groups, BioTel Care’s
customer base will be diversified with large sales accounts.
Establish relationships with commercial payors: By building on the existing relationships
with commercial insurances, the device is expected to be granted reimbursement, which is
key for successful sale-through to patients.
1 2
BioTel operates in three attractive business units that have vast potential for future growth.
The following strategic measures will accelerate organic growth in these existing business units:
Potential Add-on and Growth Plan3
BioTel can be developed into the leading player for Telehealth and Remote Medical Solutions
through strategic acquisitions of companies in the areas of virtual health and population health:
Virtual Health Care Delivery: By entering the market for Virtual Health Care, BioTel is
expected to be able to strengthen its value proposition of making health accessible to
anyone, anywhere.
Chronic Disease Management: To further develop the company towards its vision of
improving quality of life for patients with chronic diseases, BioTel can acquire competences
in areas related to chronic care.
Diabetes Data Management: As to replicate the success of BioTel’s cardiac data
management (Geneva) and to strengthen its position in the Glucose Monitoring market,
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Expand the customer base 
of the Geneva Software 
Platform (endogenous)
Value Creation Strategy – Organic Growth Acceleration
Organic growth in the Remote Cardiac Monitoring segment will be driven by the positive market 
outlook and by strengthening its internal capabilities such as its sales force and Geneva
Value Creation Strategy Rationale Strategy Description
• Maintain focus on flagship products, i.e. MCOT and
Extended Holter, constantly improving its technology
and adding value through professional services.
• Reinforce collaboration with physicians who have
prescribed BioTel Heart devices to gather potential
improvement points and strengthen its relationship.
• Leverage existing partnerships (e.g. Apple and
Fitbit) to further increase brand awareness and
strengthen BioTel’s technological leadership.
Reinforce market leadership 
in strongly growing market
(exogenous, endogenous)
Estimated Impact on BU Revenue
• Cardiac patients’ volume is expected to increase
due to the aging population as well as the increasing
awareness for health and wellness.
• Trends, such as the wide-spreading adoption of
telemedicine as well as the shift towards value-based
healthcare methods, make Remote Cardiac
Monitoring attractive.
• Recent increase of Remote Cardiac Monitoring
providers and technology development urges market
leaders to reinforce their market position.
• Increase in the number of
patients in the field of
Remote Cardiac Monitoring.
• Enlargement of sales force dedicated to expand the
number of sales accounts (practices).
• Geographical re-organization of the sales force to
improve efficiency in terms of sales accounts
(practices) managed by each salesperson.
• Strengthening of professional relationships with
commercial payors to guarantee they will keep/start
reimbursing BioTel Heart’s devices.
Enlargement of sales force 
and efficiency improvement 
(endogenous)
• Strong relationships with practices and physicians
are key in the Remote Cardiac Monitoring market,
as devices require a prescription.
• These relationships are established and maintained
through BioTel’s outside sales force.
• The prescription of medical devices and services is
particularly driven by personal preference.
• If satisfied, physicians tend to stick with the provider
to maintain consistency in diagnosis, data reports, and
to limit reimbursement refusals.
• Geneva’s strong capabilities can be cross-sold to
existing sales accounts (practices) of BioTel.
• The Remote Cardiac Monitoring sales force will be
briefed to generate multiple leads for the Geneva
platform.
• The dedicated sales team for Geneva will then
secure the subscription agreement with the sales
account and manage implementation.
• Healthcare trends towards patient data consolidation
aim to reach workflow efficiency, productivity
increase, and better service offering.
• During 2019, BioTel completed the acquisition of
Geneva Health Sciences.
• Geneva offers physicians an innovative cloud-based





5Investment Thesis | Industry Overview | Company Overview | Value Creation Strategy | Operating Model | Valuation, Capital Structure & Returns | Exit & Due Diligence
• Market share gain (US)
due to advanced MCOT and
Extended Holter devices.
• Increase in the number of
sales accounts (practices)
in the US.
• Increase in sales efficiency
impacting the number of
sales accounts.
• Increase in the number of
sales accounts (practices)
in the US.
• Stable and recurring source
of revenue due to new
subscription agreements.
January 2020
Diversification of BioTel 
Care’s customer base 
(endogenous)
Value Creation Strategy – Organic Growth Acceleration
Growth in Clinical Trial Services and Glucose Monitoring markets will be driven by positive market 
trends, relationships with insurances and partnerships with Home Care and Employer Groups
Value Creation Strategy Rationale Strategy Description
• Reinforcement of partnerships with laboratories
and physicians to sustain current cardiac and
imaging knowledge and capabilities offered.
• Reinforcement of partnerships with large CROs to
win subcontracts for specialized clinical trial services.
• Potential enlargement of Clinical Trial Research
Services offered to include Blood Glucose
Monitoring and other chronic diseases.
Leverage excellent cardiac 
expertise and partner with 
CROs (endogenous)
Estimated Impact on BU Revenue
• The current trend towards clinical trial outsourcing
as well as the rising demand for faster turnaround of
clinical trial processes will benefit specialized and
experienced clinical trial service providers.
• BioTel Research is highly specialized in cardiac and
imaging services, capabilities for which demand has
increased.
• Build relationships with commercial insurances to
be granted reimbursement for the BGM device.
• Use partnerships with commercial insurances for
marketing purposes, as patients often use devices
recommended by their commercial insurance,
leveraging the cost-saving opportunities of the
device and the value added to patients due to its
wireless connectivity.
Establish relationships 
with commercial payors 
(endogenous)
• Reimbursement is required to be relevant for diabetes
patients using glucose monitoring devices.
• A major burden for insurances is the cost of blood test
strips. BioTel does not charge for additional strips,
which is why BioTel Care’s subscription model
would allow commercial insurances to save up to
$280 per patient per year (See Appendix 22).
• Increase marketing and sales effort to establish
subscription agreements with Employer and
Elderly/Home Care Groups.
• Key targeted institutions include Elderly/Home Care
conglomerates which could aggregate all their
patients’ data using the BioTel Care platform.
• The wireless connectivity and remote monitoring
capabilities of BioTel Care’s BGM device are
technologically advanced compared to competitor
products.
• These technological advantages would allow certain
institutions, like Employers or Elderly/Home Care
Groups, to increase their value proposition towards
their clients (i.e. employees or patients). In the case of
Elderly Care Groups, efficiency could be dramatically
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• Focus on the establishment
of partnerships will win
additional sub-contracts.
High Low
• Stable revenue stream
and solid growth according
to total market growth.
• Reimbursement of BGM
device by private payors
will increase market.
• Recommendation of BGM
service to patients by
insurances.








Strengthen BioTel’s EU 
presence by leveraging 
recent acquisition 
(endogenous)
BioTel’s international presence will be reinforced by leveraging ADEA Medical’s capabilities as well 
as by the acquisition of SHL Telemedicine, the 3rd largest Cardiac Monitoring player
Value Creation Strategy Rationale Strategy Description
• Leverage ADEA Medical’s existing technology to
further improve BioTel’s product offering.
• Reduce manufacturing costs for ADEA Medical’s
devices through economies of scale.
• Leverage ADEA Medical’s established distribution
channels and network to further increase BioTel’s
presence in the European market.
• Additional identification of synergies and cost-saving
opportunities.
Estimated Impact on BU Revenue
• BioTel has acquired its first non-US location in 2019,
ADEA Medical, which offers remote cardiac monitoring
services to patients in Sweden.
• Building upon BioTel’s brand and know-how in the
Remote Cardiac Monitoring market, ADEA Medical is
expected to see accelerated growth compared to its
peers.
• Patients in the Nordics are characterized by great
awareness for health and wellness, good insurance
coverage, and lower population density, making it an
appealing market for Remote Cardiac Monitoring.
• Currently increasing regulation for medical products
entering the European market and higher difficulties in
achieving CE clearance underlines the strategy to
strengthen the EU market position through an
already established player.
• Acquisition of SHL Telemedicine, the 2nd largest
direct competitor in the Remote Cardiac Monitoring
market.
• Leverage SHL’s CE-cleared technology and
distribution channels, to further improve BioTel’s
product offer and to consolidate and expand the
presence in the EMEA region.
• Realization of synergies in relation to the production
of devices, data monitoring centers, and corporate
overhead.
• Further protect BioTel’s IP through the acquisition
of patents held by SHL Telemedicine, expanding
the IP protection coverage in the EMEA market.
Consolidation of the
EMEA Market through 
acquisition
(endogenous)
• The Remote Cardiac Monitoring market in the EMEA
region is highly fragmented, while major trends
towards telemedicine and remote patient monitoring
drive growth.
• Several factors, such as the increasing regulation of
health-related areas and higher difficulties in
achieving CE clearance for medical products, as
well as customers’ preferences towards national
product and service providers, favor the acquisition
of an existing player to expand in the EU market.
• SHL Telemedicine has been identified as BioTel’s
potential M&A target, as it has a strong presence in
the German and Israeli markets, high EBITDA margins
and relatively low valuation compared to other potential
targets.
Remote Cardiac Monitoring
Value Creation Strategy – Internationalization Reinforcement 2
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High Low
• Increase in the number of
sales accounts (practices)
in the EU.
• Establish BioTel’s presence
in the EU market.
• Consolidation of 2nd largest
direct Remote Cardiac
Monitoring competitor.
• Expansion of customer
base and acquisition of new
distribution channels.
January 2020
By acquiring SHL Telemedicine, BioTel will consolidate the European market and reinforce its 
international presence
Business Desription1
• SHL Telemedicine is the current 3rd largest Cardiac
and Pulmonary Monitoring player in the market, with
a strong and established presence in EMEA, offering
centralized remote diagnostic and monitoring services
to patients and physicians.
• The firm offers remote monitoring devices to detect
cardiac arrythmias and runs 24/7 monitoring centers
which analyze transmitted data and report to physicians.
• SHL’s positioning and capabilities make it an attractive
target for consolidation and cost synergies.
EMEA Presence
• Strong position in the German and Israeli markets,
kickstarting BioTel’s presence in EMEA.
• CE cleared products and contractual relationships with
commercial payors, which offer great positioning for
further expansion to other EU markets.
Product, Client and IP Portfolios
• Its product portfolio includes cardiac and pulmonary
monitoring devices with remote data transmission; all
devices bear CE clearance and the majority is also
cleared by the FDA in the US.
• Relationships include leading names in the health
sector, including health insurances and commercial
payors, hospitals, group medical practices, individual
healthcare professionals and distributors.
• The largest payors include AOK (largest German public
insurance), and Maccadi (largest insurance in Israel).
• The company owns eight patents in the US to protect
the technology of its products and services, which are
expiring through 2035.





















SHL Telemedicine, based in Israel, is
an established Remote Cardiac
Monitoring player.
Its strong EMEA market presence
and service synergies make SHL a
robust target to reinforce BioTel’s
international presence and to
consolidate the global market.
Acquisition Overview Acquisition Rationale
Revenue and EBITDA Contribution: Additional revenue and EBITDA from
international markets, diversifying market risk.
Operational Synergies: Cost synergies are expected to be realized on the cost
of revenue (through scale) and corporate overhead.
Multiple Arbitrage: Given SHL Telemedicine’s lower acquisition EV/EBITDA
multiple, the firm’s consolidation will be subject to multiple arbitrage.
Revenue & EBITDA Contribution, In $mn
Acquisition Year
High Low
Value Creation Strategy – Internationalization Reinforcement – Acquisition of SHL Telemedicine 2
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By adding further telehealth capabilities to its current product and service portfolio, BioTel can be 
formed into the leading telemedicine company in the US and abroad
Sources: Glooko Website; Sentinel Website; SleeopOn Website; Itamar Medical Website; CareClix Website; MDLive Website; On-Call Website
Remote Cardiac Monitoring Cardiac Data Management Remote Glucose Monitoring Diabetes Data Management Chronic Disease Management Virtual Health Care Delivery
Cardiac Monitoring Population Health Management
Vision: BioTelemetry is the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care
Diabetes Data Management Chronic Disease Management Virtual Health Care Delivery
By entering the market for Virtual Health Care, BioTel can
strengthen its value proposition of making health accessible to
anyone, anywhere.
Potential Acquisition Targets:
• CareClix is the industry leader in software and services for
telemedicine and virtual health. Its solutions – built on the
CareClix platform – revolutionize the way hospitals and other
clinical care facilities operate and interact with patients.
• MDLive provides patients, health plans, health systems and
self-insured employers with access to board-certified doctors.
• On-Call provides a cloud-based virtual care solution to connect
healthcare clinics and healthcare organizations with patients.
As to replicate the success of BioTel’s cardiac data management
(Geneva) and to strengthen its position in glucose monitoring,
BioTel canacquire capabilities for diabetes management.
Potential Acquisition Targets:
• Glooko develops software and tools for diabetes management,
improving health outcomes for people with diabetes and
providing an efficient data management platform for clinics and
health systems. With Glooko, it is possible to synchronize 95%
of all available diabetes devices.
To further develop the company towards its vision of improving
quality of life for patients with chronic diseases, BioTel
canacquire competences in areas related to chronic care.
Potential Acquisition Targets:
• Sentinel provides patients with an FDA-approved, Bluetooth-
enabled blood pressure device. Its HIPAA-compliant mobile
app enables two-way communication between patients and
their care teams.
• SleepOn provides a new generation of AI device to track sleep,
screen sleep apnea and improve sleep health.
• Itamar Medical offers unique, comprehensive sleep solutions,
combining diagnostics and therapy of sleep apnea.
1 2 3
1 2 3
Value Creation Strategy – Potential Add-on and Growth Plan 3
Virtual Health
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Value Creation Strategy – Risk Profile
The implementation of the value creation strategy faces some unlikely risks, but strategies are in 
place to mitigate their potential impact
Value Creation Strategy Risks
Reinforce market leadership 
in a strongly growing market
• Perspective of robust future market growth attracts new entrants.
Enlargement of sales force 
and efficiency improvement
• Sales personnel incapable of achieving higher efficiency levels.
• Increase in sales force is not translated into higher revenues for
BioTel Heart.
Expand the customer base 
of the Geneva Platform 
• BioTel’s current customer base not interested in subscribing for
Geneva Software Platform.
Strengthen EU presence
• ADEA Medical’s early stage.
• Strong competition makes it difficult for BioTel to obtain a greater
market share in the European market.
Consolidation in EMEA
• Post-merger integration process does not go as planned due to the
lack of market success and cultural fit between SHL
Telemedicine and BioTel.
Leverage cardiac expertise 
and partner with CROs
• Enlargement of Clinical Trial Services portfolio to Blood
Glucose Monitoring and other chronic diseases takes more time
to implement than predicted in the Operating Model.
Establish relationships with 
commercial payors
• Not possible to change the business model of BioTel Care and
grant reimbursement of the BGM device.
• Establishment of subscription agreements with Employer and
Elderly/Home Care Groups might not be possible or takes more
time to implement than expected.
Probability of Occurrence
High barriers to entry
No guarantees about future sales 
personnel hiring and efficiency
Dependent on external decision
(i.e. the physician)
High uncertainty due to ADEA 
Medical’s early stage
Established firm with similar 
business model
BioTel is expected to have the 
necessary capabilities to offer 
this service 
Agreements with insurance 
companies are subject to big 
negotiation
Dependent on external decision
(by Employer and Elderly/Home 
Care Groups)
Mitigation Strategies
• Patents protecting key capabilities.
• Leverage on its superior brand
recognition for innovation and quality.
• Extensive training sessions to support
the recent hires.
• Management Equity Program.
• Exploit the strong background in
early-stage acquisitions.
• Close monitoring its initial steps.
• Thorough DD process prior to the
acquisition.
• Consult PE fund expertise and solid
M&A background.
• Collaboration of BioTel Care when
expanding BioTel Research into the
BGM market.
• Implement free trial month to test the
device and recognize its technical
advantages.
• Sales team dedicated to this strategy.
• Implement free trial month.
• Sales team dedicated to this strategy.
• Implement free trial month to test the
Geneva Software Platform.
Diversification of BioTel 
Care’s customer base




Income Statement Overview 
D&A & Net Working Capital 
CAPEX & Unlevered FCF
Strategic Value Creation Levers
January 2020
Operating Model – Income Statement Overview
Revenue, Gross Profit and EBITDA are expected to experience strong growth driven by the 
proposed value creation strategy






In $mn 2019B 2020E 2021E 2022E 2023E 2024E 2025E CAGR
Total Revenue 475.3 580.9 717.3 781.8 821.9 874.6 935.4 11.9%
BioTel Heart 410.1 509.0 637.6 693.5 715.5 750.9 795.8 11.7%
BioTel Research 55.4 60.9 66.9 73.6 80.8 88.9 97.6 9.9%
BioTel Care 5.0 5.2 5.6 7.0 17.4 26.1 32.6 36.5%
BioTel Alliance 4.8 5.8 7.2 7.8 8.2 8.7 9.4 11.9%
in % of Revenue
BioTel Heart 86.3% 87.6% 88.9% 88.7% 87.1% 85.9% 85.1%
BioTel Research 11.7% 10.5% 9.3% 9.4% 9.8% 10.2% 10.4%
BioTel Care 1.1% 0.9% 0.8% 0.9% 2.1% 3.0% 3.5%
BioTel Alliance 1.0% 1.0% 1.0% 1.0% 1.0% 1.0% 1.0%
(-) Cost of Revenue 173.4 201.0 246.0 265.2 290.5 309.9 327.6 11.2%
in % of Revenue 36.5% 34.6% 34.3% 33.9% 35.4% 35.4% 35.0%
Gross Profit 301.9 379.9 471.3 516.6 531.4 564.7 607.8 12.4%
in % of Revenue 63.5% 65.4% 65.7% 66.1% 64.6% 64.6% 65.0%
(-) Operating Expenses 200.2 244.6 295.2 319.6 337.6 351.2 375.3 11.0%
in % of Revenue 42.1% 42.1% 41.1% 40.9% 41.1% 40.2% 40.1%
SG&A 139.8 167.9 200.4 214.4 227.0 233.5 249.4 10.1%
Selling & Marketing 48.7 58.1 64.9 70.5 75.8 81.3 86.7 10.1%
General & Administrative 91.0 109.8 135.6 143.9 151.2 152.1 162.8 10.2%
R&D 18.2 25.1 31.0 35.7 37.6 40.0 42.8 15.3%
Provision For Doubtful Acc. 23.8 29.1 36.0 39.2 41.2 43.9 46.9 11.9%
Other Operating Expenses 18.4 22.5 27.7 30.2 31.8 33.8 36.2 11.9%
EBITDA 101.8 135.3 176.1 197.0 193.7 213.5 232.5 14.8%
in % of Revenue 21.4% 23.3% 24.6% 25.2% 23.6% 24.4% 24.9%
(-) D&A 51.9 56.9 51.0 68.0 72.5 72.9 73.7 6.0%
in % of Revenue 10.9% 9.8% 7.1% 8.7% 8.8% 8.3% 7.9%
Operating Income / EBIT 49.8 78.4 125.1 129.0 121.2 140.6 158.8 21.3%











• Total revenue is expected to increase at a robust CAGR of 11.9% from 2019 to 2025,
particularly driven by the strong performance of BioTel Heart.
BioTel Heart
Main Revenue Growth Drivers:
• The development of the reimbursement rates as well as the total patient volume.
• The reimbursement rates are subject to limited influence as they are set by the public CMS, but
the patient volume is expected to grow over the investment period due to an overall increase in
the number of treated patients and in the number of sales accounts of BioTel Heart.
• Further revenue growth stems from the vast growth of the Geneva Software Platform as well as
from an internationalization effort including leveraging on the recent buyout of ADEA Medical
and the acquisition of the 2nd largest direct competitor, SHL Telemedicine.
BioTel Research
Main Revenue Growth Drivers:
• The strong market growth, competitive advantages of BioTel and the reinforcement of
partnerships with laboratories, physicians and multinational CROs.
BioTel Care
Main Revenue Growth Drivers:
• The establishment of partnerships with commercial payors and the diversification of BioTel
Care’s customer base, which will boost patient volume.
BioTel Alliance
• The growth of this BU is expected to remain constant as percentage of total revenue as it is
solely considered to be assisting work for the other business units.
Gross Profit
• Gross Profit is expected to increase over the investment period due to the growth in revenue, as
well as operational improvements reducing, or stabilizing cost of goods sold.
EBITDA
• EBITDA is expected to more than double over the investment period as the slightly increasing
fixed costs, particularly for SG&A and R&D, are offset by the strong revenue growth and
overhead efficiencies.
Notes: 2021E onwards includes SHL Telemedicine. Sources: Team Assessment
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Operating Model – D&A & Net Working Capital
Depreciation, Amortization and Net Working Capital are expected to increase according to the high 
growth of BioTel, while the Cash Conversion Cycle is expected to remain at similar levels













• DIO: Inventory is not essential for the nature of BioTel’s major business, as it is particularly
focused on the delivery of the service; hence, the amount of inventory was forecasted to
remain at historical levels, but DIO is expected to improve due to operational
improvements.
• DSO: Given that public reimbursement accounts for a significant part of sales, DSO was
assumed to remain stable converging back to 30.0 days after the SHL acquisition in 2021.
• DPO: Due to larger scale and supplier bargaining power as proven market leader, DPO
is expected to be impacted positively and move from approximately 38 days payables
outstanding to almost 42 days.
• Other Current Liabilities are expected to develop at their historical ratio over sales, which
equaled approximately 6.5%.
In Days 2019B 2020E 2021E 2022E 2023E 2024E 2025E
DIO 15.6 15.6 16.9 16.5 16.1 16.2 16.0
DSO 30.0 30.0 31.0 30.7 30.4 30.4 30.0














2019B 2020E 2021E 2022E 2023E 2024E 2025E
Depreciation Amortization D&A
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• Depreciation was determined based on Total CAPEX as well as on the historical
weighted average useful life of PPE, which equaled 4.1 years1 for BioTel and 8.5 years for
SHL.
• Amortization relates to Other Intangibles only (i.e. excluding Goodwill). These assets were















n • Depreciation is expected to increase from $37.6mn in 2019 to $60.9mn in 2025, which is
driven by increasing CAPEX (See next Page) that is required to support the level of sales
to be achieved and to a smaller extent by the acquisition of SHL Telemedicine in 2021.
• At the same time, the average life of PPE is expected to remain at historical levels as the
majority of PPE will continue to be remote cardiac monitoring devices.
• Amortization is expected to slightly decrease from $14.3mn in 2019 to $12.8mn in 2025,
which is attributed to the relatively low investment in Intangible Assets, which intends
to keep intellectual property protection at stable and secure levels.
• At the same time, amortization is expected to remain at historical levels of % of Intangible
Assets.
Notes: 2021E onwards includes SHL Telemedicine; 1The low useful life is because the majority of PPE is composed by cardiac monitoring devices which have an average useful life of 4 years; BioTel leases its facilities. Sources: Team Assessment
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Operating Model – CAPEX & Unlevered FCF
BioTel’s Unlevered FCF grows at a strong CAGR of 19.4%, which is driven by higher growth of the 
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EBITDA Operating Cash Flow Unlevered FCF





• Total CAPEX was broken down into CAPEX for PPE and Intangibles, whereas CAPEX
for PPE was further broken down into CAPEX for Maintenance and Growth.
• Intangibles CAPEX includes required investments in intellectual property that is



















• PPE Maintenance CAPEX will continue to account for the vast part of CAPEX, which is
attributed to the significance of the remote cardiac monitoring services.
• The nature of this business requires the maintenance of the devices that are sent out
to patients for the prescribed monitoring period, returned and reused for other patients.
• PPE Growth CAPEX is expected to be higher in the first years of the investment
period, as an investment in additional remote cardiac monitoring devices has to be made.
• Throughout the period, however, the growing share of high-value services will limit the
required investment as the forecasted level of sales can be achieved with fewer devices.
In $mn 2019B 2020E 2021E 2022E 2023E 2024E 2025E CAGR
EBITDA 101.8 135.3 176.1 197.0 193.7 213.5 232.5 14.8% 
(-) Statutory Tax Expense 10.5 16.5 26.3 27.1 25.5 29.5 33.4 21.3% 
Operating Cash Flow 91.3 118.8 149.9 169.9 168.3 184.0 199.1 13.9% 
(-) D in Net Working Capital 1.5 9.8 (3.4) 8.8 (10.9) 15.0 (9.6) n.a.
(-) CAPEX 40.0 68.9 68.6 64.1 61.8 65.6 64.2 8.2% 
Investing Cash Flow 41.5 78.8 65.2 72.8 50.9 80.6 54.6 4.7%


















• Operating CF is expected to grow at a strong CAGR of 13.9% from 2019 to 2025, which is
particularly attributed to the strong EBITDA growth.
• The downside effect in 2024 is due to the significant increase in Accounts Receivable
compared to 2023, which saw sales growth slow given the reimbursement rate adjustment
for the Extended Holter.
• Unlevered FCF is expected to grow at a significant CAGR of 19.4% from 2019 to 2025,
which is again attributed to the strong EBITDA growth and relatively stable NWC and CAPEX
requirements.
• The slump in 2024 is due to the reimbursement rate adjustment for the Extended Holter in
2023 and its subsequent impact.
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Notes: 2021E onwards includes SHL Telemedicine. Sources: Team Assessment
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Revenue is expected to increase by almost 97% from $475mn in 2019 to $935mn in 2025
• Reimbursement: Reimbursement rates are expected to be slightly lowered, curbing revenue
growth with an estimated impact of $82mn.
• Market Growth: The market development, particularly in the field of Remote Cardiac Monitoring,
is seen greatly positive and will contribute $190mn, ceteris paribus.
• Sales Push: The growth of BioTel’s outside sales force and specific efficiency improvement
measures, such as the geographical re-organization, are expected to have an impact of $100mn.
• Geneva and ADEA Medical: Realizing the potential of the Geneva Software Platform and the
recent Swedish acquisition, ADEA Medical, will add $84mn and $16mn, respectively.
• SHL Telemedicine: The acquisition of direct competitor SHL Telemedicine is expected to boost
BioTel’s revenue with its contribution of $77mn.
• BioTel Research, Care and Alliance: BioTel’s other business units are majorly expected to
benefit from positive market environments and contribute $42mn, $28mn and $5mn, respectively.
Operating Model – Impact of Strategic Value Creation Levers
Key levers for growth in the operating model of BioTel are market growth, the proposed sales push, 
the growth of the Geneva Software Platform and the acquisition of SHL Telemedicine 
Revenue & EBITDA Growth
The evolution of BioTel’s revenue and EBITDA is driven by an attractive development of all markets the target company operates in, as well as the proposed specific value creation levers. The
extent of the impact differs across all levers, while the greatest contribution of growth is clearly generated in the main business unit BioTel Heart.
EBITDA is expected to increase by approx. 128% from $102mn in 2019 to $232mn in 2025
• Organic Growth: Total EBITDA is expected to grow by approx. $83mn due to the vast organic
growth, particularly in the business unit BioTel Heart (See Chart above), which will significantly
increase its volume of patients driven by the overall market growth in the US and the sales push.
• SHL Telemedicine: Non-organic EBITDA growth is coming from the strategic acquisition of SHL
Telemedicine, which will contribute $15mn; SHL’s profitability, yet at lower levels than BioTel’s, is
expected to improve due to the transfer of know-how, economies of scale and other realized cost
synergies, particularly in overhead.
• Operational and Overhead Efficiencies: The existing cost structure, which sees the costs for the
provision of remote cardiac monitoring services (i.e. the monitoring centers) and costs for sales as
the major drivers, has vast potential for efficiency improvements; with growing scale, an increasing
focus on high-value services, such as the MCOT and synergies in sales, such as for the Geneva
Software Platform, BioTel is expected to improve its EBITDA by the total of $33mn.
BioTel Heart
exogenous endogenous


















Operating Model – Revenue – BioTel Heart
Despite reimbursement risk, remote cardiac monitoring services revenue is expected to rise 
through significant increases in the # of patients

























Development of the reimbursement rates
• The future reimbursement rates for the services delivered by BioTel are projected to face
slight reductions until reaching constant levels in late 2024.
• The reduction in Extended Holter reimbursement rates is expected to occur between 2021-
2023 as the code is transitioned into permanent category, with cuts between 30-85%.
• The payors mix of BioTel is expected to remain constant with reimbursement of 35% from
Medicare and 65% from commercial insurances, assuming the latter pay a premium of
5% on top of public rates.
Increase in sales force and sales efficiency will grow the # of sales accounts
• An expansion of the sales force of BioTel as well as efficiency improvements will significantly
drive revenue by signing additional sales accounts.
• The sales force expansion schedule sees an overall increase of 43 FTE in sales by 2025;
while new-hires are not expected to achieve the same amount of signings in their initial year,
extensive training is intended to support quick pick up of pace.
• In terms of sales efficiency, geographical re-organizations will enable sales personnel to
oversee more sales accounts on average, from 12 in 2019 to 16.5 from 2021 onwards.
120 140 150 155 158 161 163
1 380 1 533
1 608 1 639 1 658 1 676 1 689
2019B 2020E 2021E 2022E 2023E 2024E 2025E
BioTel Heart Sales Force and # of Sales Accounts
Sales Personnel, in FTE Sales Accounts
Revenue in the BioTel Heart BU comes from three different sources: remote cardiac monitoring services, the Geneva Software Platform and the newly acquired, direct competitor SHL Telemedicine.
Remote cardiac monitoring services are expected to remain the major contributor to the BU’s total revenue. The main revenue growth drivers are the development of the reimbursement rates and the
patients’ volume. While the first one is subject to limited influence, the latter can be determined by an increased effort in sales activities.
Total # of patients per account will rise driven by technological advancement
• Overall, the number of patients per account is predicted to rise due to strong market growth
and the anticipated awareness for the efficiency of remote cardiac monitoring solutions.
• For recent technologies (i.e. MCOT or Extended Holter), the number of patients per
account is expected to increase at higher rates, as these solutions offer technological
advantages that enable higher diagnosis yields and more efficient workflow for physicians.
• For other technologies (i.e. Event or Traditional Holter), modest growth rates are
expected; while still relevant for initial diagnosis, these solutions are replaced by newer
technologies.
Sources: Kerrisdale Capital – “iRhythm Technologies, Inc. (IRTC) Growth Reversal will Leave Investors Heartbroken” (2019); Team Assessment 
46 69 90 103 113 119 125
160 165 170 171 173 171 170
213 231 249 264 280 291 303
417 430 438 447 451 456 456 
2019B 2020E 2021E 2022E 2023E 2024E 2025E
Total # of Patients per Sales Account
Extended Holter Event MCOT Traditional Holter
Reimbursement Rate, In $ 2019B 2020E 2021E 2022E 2023E 2024E 2025E
MCOT 981.6 982.1 965.9 950.0 934.3 918.8 918.8
Traditional Holter 50.4 50.4 49.4 48.4 47.5 46.5 46.5
Extended Holter 336.2 340.4 340.4 340.4 136.1 136.1 136.1
Event 274.9 274.4 270.7 267.0 263.4 259.9 259.9
16Investment Thesis | Industry Overview | Company Overview | Value Creation Strategy | Operating Model | Valuation, Capital Structure & Returns | Exit & Due Diligence
January 2020
Operating Model – Revenue – BioTel Heart
Development of the platform and an increased sales effort will drive the revenue for Geneva, while 
the acquisition of SHL Telemedicine will contribute significant revenue generated abroad



















Bi-annual price increment due to update of Geneva’s technology and capabilities 
• The annual price, consisting of subscription and service fees paid by the sales accounts
(practices), will increment every two years over the investment period until 2025.
• As the Geneva Software Platform is an important pillar in the value creation strategy, the
platform will see dedicated investments into its further development; hence, bi-annual
updates with technological improvements and the introduction of new capabilities and
features (e.g. telehealth capabilities) explain this price increment.
• Following this strategy, BioTel is also expected to achieve higher customer retention rates as
it is predicted to incentivize practices to continue using the platform.
ADEA Medical and SHL Telemedicine will contribute for the revenue generated abroad
• In July 2019, BioTel acquired ADEA Medical, a telemedicine company based in the
Nordics and responsible for providing remote cardiac monitoring services.
• In order to reinforce BioTel’s international presence and to consolidate the Remote Cardiac
Monitoring market, BioTel is going to acquire SHL Telemedicine in 2021.
• SHL Telemedicine will also provide direct access to patients, physicians, and insurances.
• Both acquisitions offer vast potential for growth beyond the investment period and are
going to enable BioTel to diversify its customer base while capturing some additional
market share in the European market.
Vast potential to grow the # of sales accounts (practices) for Geneva
• Due to the early stage of Geneva, there is vast potential to grow the # of sales accounts
for the software platform.
• BioTel will take advantage of the existing BioTel Heart customer portfolio, consisting
of more than 1,000 accounts that already prescribe remote cardiac monitoring services
provided by the target company.
• In order to achieve high growth rates in the early stages of the investment, the BioTel Heart
sales force will be trained and advised to generate leads for the Geneva Software
Platform, which will then be handed over to the dedicated sales and implementation team.
The Geneva Software Platform is expected to be the second-largest contributor to BioTel Heart‘s revenue by 2025. Its main revenue drivers are the average price, consisting of subscription and






















2019B 2020E 2021E 2022E 2023E 2024E 2025E
Total # of Sales Accounts (Geneva)
165 165 181 181
199 199 209
2019B 2020E 2021E 2022E 2023E 2024E 2025E
Price Development, In $k
1 4 8







2019B 2020E 2021E 2022E 2023E 2024E 2025E
Revenue Contribution from Internationalization Strategy, In $mn
ADEA Medical SHL Telemedicine Total Contribution
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Operating Model – Revenue – BioTel Research & BioTel Care
Revenue coming from Clinical Trial Services and Glucose Monitoring will be driven by the 
reinforcement of strategic partnerships and the expansion of the customer base
BioTel Research and BioTel Care – Revenue Drivers
Revenue in BioTel Research is expected to grow at the market pace, driven by the trend towards the outsourcing of Clinical Trial Services and the reinforcement of partnerships with key players
in the market. As for BioTel Care, robust and strong revenue growth is expected, driven by the introduction of reimbursement for BioTel Care’s BGM device and the enlargement of the customer
base.
































s Reinforcement of therapeutic expertise and strategic partnerships
• BioTel is expected to maintain an outstanding value proposition of expertise and experience,
which will enable them to grow at the Clinical Trial Services market pace during the
investment period, which equals an attractive CAGR of 9.9% for the period of 2019-2026.
• Key strategic levers include the strengthening and expansion of partnerships with central
laboratories, Pharmaceutical and Biotech companies as well as with multinational CROs,
such as Covance, PPD and PRA.
• These strategic partnerships will create opportunities in the award of (sub-)contracts
requiring Remote Cardiac Monitoring and medical imaging capabilities.
Diversification of the customer base with mutually beneficial partnerships 
• Dedicated Home Care Organizations, such as Kindred at Home or Interim Healthcare –
each serving approximately 100,000 patients per year – are attractive sales targets for
BioTel Care, as its value proposition fits the need of their workforce for remote medical
devices improving workflow efficiency.
• Monitoring the blood glucose of a large number of Home Care patients with diabetes would
save significant amounts of costs related to nursing time, such as logistic costs and
opportunity costs.
• The impact of this strategy is also expected to accelerate in the second half of the period.
Partnering with commercial insurances creates access to diabetes patients
• As reimbursement is key for diabetes patients to choose one device over another, BioTel
will seek agreements with key commercial insurances, such as United or Aetna.
• This will provide access to all insured diabetes patients of BioTel’s commercial partners.
• Moreover, these insurances are expected to play an important role in the marketing
and advertisement of glucose monitoring services, as they are incentivized to
recommend technologically advanced solutions covered by their health plans.
• Due to the lead time, the impact of this strategic effort will only accelerate in the second half
of the investment period.
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Operating Model – Gross Profit & EBITDA
BioTel is expected to realize operational and overhead efficiencies supporting the increment in the 
Gross Profit and EBITDA Margin that is driven by significant revenue growth
Gross Profit and EBITDA Drivers
The value creation over the projected investment period is majorly supported by the significant revenue growth across all business units. Operational and overhead efficiencies, however, provide further
levers for the improvement of the variable and fixed cost base, which will positively impact the overall profitability of BioTel.
Operational efficiencies
• Overall, the total gross margin (in % of revenue) is expected to increase from 63.5% in
2019 to 65.0% in 2025, the projected final year of the investment period.
• BioTel Heart will experience an overall slight increase of approximately 60bps to 68.0% in
2025. This is driven by the following:
• An optimized mix of remote cardiac monitoring services, with more high-value
services (i.e. Extended Holter and MCOT) requiring less manufactured devices while
achieving higher reimbursement.
• The increasing revenue contribution of the Geneva Software Platform, which realizes
lower cost-intensity due to the nature of its business.
• BioTel Research, which is subject to a relatively higher cost of revenue, is expected to move
towards historical levels to 42.6% in 2025, representing an increase of 500bps.
• BioTel Care, due to the similarity of the business model with Remote Cardiac Monitoring, is
expected to see comparable gross margin to the monitoring business of BioTel Heart.
Overhead efficiencies
• Overall, the total EBITDA margin (in % of revenue) is expected to increase from 21.4%
in 2019 to 24.9% in 2025, the projected final year of the investment period.
• The positive improvement of 350bps stems from realized efficiencies in the overhead
expenses that are expected to be maintained at the same or even slightly lower levels (in %
of revenue) due to the following:
• An optimized mix of remote cardiac monitoring services, with more high-value
services (i.e. Extended Holter and MCOT).
• The growing importance of highly profitable revenue streams, such as the Geneva
Software Platform and Glucose Monitoring.
• Economies of scale, particularly regarding SG&A and R&D, that are realized with the
organic and non-organic (i.e. the acquisition of SHL Telemedicine) growth of BioTel.
• The slight decrease in 2023 is due to the expected cut in the reimbursement rate of the














67% 69% 69% 69% 68% 68% 68%
38% 41% 42% 42% 42% 42% 43%
67% 68% 69% 69% 67% 67% 68%
29% 29% 29% 29% 29% 29% 29%
2019B 2020E 2021E 2022E 2023E 2024E 2025E
Gross Margin per business unit, In % of Revenue
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EBITDA Margin, In % of Revenue





This Work Project provided me with the chance to deepen and test my knowledge of private equity 
and develop and understanding of the importance of an outstanding value creation strategy
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BioTelemetry, Inc. is the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care
Hard Skills
• Research: conducting thorough and creative company and industry research to develop
exhaustive knowledge of several unique markets within a short period of time.
Which hard and soft skills did you develop dur ng he project?1
Soft Skills
• Financial Modelling: creating user-friendly Leveraged Buyout model from scratch,
including the Operating Model, Capital Structure, Valuation and Returns.
• Value Creation Strategy: identifying company specific value creation levers and creating a
tailored business plan, taking into account opportunities and risks.
• Communication: inter-personal communication in constant contact with team members
and in problem solving sessions.
• Time Management and Prioritization: setting specific, but also the right goals to deliver
value-adding output within a short period of time.
• Maintaining the bigger picture: working on a project requiring a great amount of different
analyses and tasks, I started developing an eye for the big picture.
What would you change in your individual or team approach if you had to do a similar project?3
Individual Approach Team Approach
• Set weekly (daily) goals.
• Set regular weekly meetings and prepare clear goals for each team member, including
check-in’s at the beginning of the meeting and check-out’s in the end.
• Set up environment of (even more) open and intense discussion of the work from the
beginning.
• Find additional ways to reach out to more industry experts, to get more insights.
General
• Deal with an intense workload while complying with strict deadlines.
How did the Master in Finance at Nova SBE prepare you for the project?2
Private Equity Course
• The comprehensive education in (almost) all fields of Finance, but with an extensive focus
on Corporate Finance.
• The ability to work with people, due to the importance of group projects across all courses.
• Spark my academic and practical interest in the fascinating world of Private Equity.
• Teach me the comprehensive basics of an investment, including target identification,
company and industry assessment and deal structure.
• Draw my attention towards the relevant factors to considered from the PE perspective when
preparing an Investment Committee Paper.
